Literature DB >> 18406682

Growth hormone-releasing peptide and its analogues Novel stimuli to growth hormone release.

M Korbonits1, A B Grossman.   

Abstract

GHRPs are oligopeptides with GH-releasing effects in humans when given by either parenteral or oral routes; in addition, nonpeptide pharmacologic analogues have recently been synthesized. Although the exact mechanism of action of these agents has not been fully established, there is probably a dual site of action on both the pituitary and the hypothalamus, possibly involving regulatory factors in addition to GHRH and somatostatin. GHRPs and their analogues may have a potential role in the treatment of short stature in children or in other situations of GH deficiency, such as adult GH deficiency, obesity, catabolic states, and even normal old age.

Entities:  

Year:  1995        PMID: 18406682     DOI: 10.1016/1043-2760(94)00204-h

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  18 in total

1.  [Molecular analysis of the human "growth hormone secretagogue"-receptor].

Authors:  S Petersenn; M Penshorn; F U Beil; H M Schulte
Journal:  Med Klin (Munich)       Date:  1999-04-15

2.  Acute decrease in circulating T3 levels enhances, but does not normalise, the GH response to GHRP-6 plus GHRH in thyrotoxicosis.

Authors:  S O Nascif; M H Senger; J C Ramos-Dias; A M J Lengyel
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

3.  Presence of ghrelin in normal and adenomatous human pituitary.

Authors:  M Korbonits; M Kojima; K Kangawa; A B Grossman
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 4.  Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system.

Authors:  E Arvat; L Gianotti; R Giordano; F Broglio; M Maccario; F Lanfranco; G Muccioli; M Papotti; A Graziani; E Ghigo; R Deghenghi
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 5.  The metabolic effects of growth hormone in adipose tissue.

Authors:  Valéria Ernestânia Chaves; Fernando Mesquita Júnior; Gisele Lopes Bertolini
Journal:  Endocrine       Date:  2013-02-21       Impact factor: 3.633

6.  Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome.

Authors:  G Grugni; G Guzzaloni; F Morabito
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

7.  Effects of the combined administration of hexarelin, a synthetic peptidyl GH secretagogue, and hCRH on ACTH, cortisol and GH secretion in patients with Cushing's disease.

Authors:  E Arvat; J Ramunni; R Giordano; B Maccagno; F Broglio; A Benso; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

Review 8.  Ghrelin, hypothalamus-pituitary-adrenal (HPA) axis and Cushing's syndrome.

Authors:  Roberta Giordano; Andreea Picu; Fabio Broglio; Lorenza Bonelli; Matteo Baldi; Rita Berardelli; Ezio Ghigo; Emanuela Arvat
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

9.  Lack of effect of hexarelin on TRH-induced TSH response in normal adult man.

Authors:  M Arosio; G Casati; O Biella; S Porretti; B P Imbimbo; G Faglia
Journal:  J Endocrinol Invest       Date:  1998-04       Impact factor: 4.256

10.  Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.

Authors:  J Bellone; E Bartolotta; C Sgattoni; G Aimaretti; E Arvat; S Bellone; R Deghenghi; E Ghigo
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.